Advertisement

Treatment of Adult HIV Infection: Antiretroviral Update and Overview

  • Author Footnotes
    1 Susan Orsega, MSN, CRNP, is an officer in the US Public Health Service and is assigned to the National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD.
    Susan Orsega
    Footnotes
    1 Susan Orsega, MSN, CRNP, is an officer in the US Public Health Service and is assigned to the National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD.
    Search for articles by this author
  • Author Footnotes
    1 Susan Orsega, MSN, CRNP, is an officer in the US Public Health Service and is assigned to the National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD.

      Abstract

      Up-to-date guidelines for nurse practitioners are critically important to keep up with the continuous advances in HIV treatment. With a key understanding of viral replication, combination therapy, treatment failure, and drug toxicities, the provider is able to have these reference tools to assist in monitoring the infection. Research development continues with a focus on new classes to inhibit different parts of the HIV cycle and drug class resistance and to determine the first- and second-line antiretroviral therapy. The purpose of this article is to provide an overview of the highly active antiretroviral therapy, basic understanding of when to initiate therapy, how to manage patients receiving these medications, treatment regimens, and useful guidelines.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Joint United Nations Programme on HIV/AIDS (UNAIDS)
        2006 Report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland2006 (Accessed April 20, 2007.)
        • Hammer SM
        • Katzenstein DA
        • Hughes MD
        • et al.
        A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
        N Engl J Med. 1996; 335: 1081-1090
        • Palella FJ
        • Delaney KM
        • Moorman AC
        • et al.
        Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
        N Engl J Med. 1998; 338: 853-860
        • Department of Health and Human Services
        Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Department of Health and Human Services, Rockville, MD2006
        • Hammer SM
        • Saag SM
        • Schechter M
        • et al.
        Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
        JAMA. 2006; 296: 827-843
        • Anderson VL
        • Orsega SM
        Edmunds ME Mayhew MS Pharmacology for the Primary Care Provider. 2nd ed. Elsevier Mosby, St Louis, MO2004: 710-720
        • Flexner C
        Brunton LL Lazo JS Parker KL Goodman and Gillman's The Pharmacological Basis of Therapeutics. 11th ed. McGraw Hill, New York, NY2006: 1280-1310
        • Fauci AS
        • Lane HC
        Kasper DL Fauci AS Longo DL Braunwald E Hauser SL Jameson JL Harrison's Principles of Internal Medicine. 16th ed. McGraw Hill, New York, NY2005: 1123-1139
        • Peyriere H
        • Reynes J
        • Rouanet I
        • et al.
        Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.
        J Acquir Immune Defic Syndr. 2004; 35: 269-273
        • Gallant JE
        • Staszewksi S
        • Pozniak A
        • et al.
        Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients.
        JAMA. 2004; 292: 191-201
        • Morse CG
        • Kovacs JA
        Metabolic and skeletal complications of HIV infection.
        JAMA. 2006; 296: 844-854
        • Aberg JA
        • Gallant JE
        • Anderson J
        • et al.
        Primary care guidelines for the management of persons infected with human immunodeficiency virus; recommendations of the HIV medicine association of the Infectious Diseases Society of America.
        Clin Infect Dis. 2004; 39: 609-629
        • Kopp JB
        • Miller KD
        • Mican JM
        • et al.
        Crystalluria and urinary tract abnormalities with indinavir.
        Ann Intern Med. 1997; 127: 119-125
        • Lalezari JP
        • Henry K
        • O'Hearn M
        • et al.
        Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
        N Engl J Med. 2003; 348: 2175-2185
      1. Penny MA, Boucher M, Man M, et al. Pharmacogenetic analysis of polymorphisms in chemokine receptors CCR5 and CCRT with respect to safety and tolerance of maraviroc (abstract H-1099). Presented at the 45th Interscience Conference of Antimicromobial Agents and Chemotherapy, December 16–19, 2005, Washington, DC.

        • Osterberg L
        • Blaschke T
        Adherence to medication.
        N Engl J Med. 2005; 353: 487-497
        • Baylor MS
        • Johann-Liang R
        Hepatoxicity associated with nevirapine use.
        J Acquir Immune Defic Syndr. 2004; 35: 538-539
        • Sanne I
        • Mommeja-Marin H
        • Hinkle J
        • et al.
        Severe hepatoxicity associated with nevirapine use in HIV infected subjects.
        J Infect Dis. 2005; 191: 825-829
        • Eron Jr, J
        • Yeni P
        • Gathe Jr, J
        • et al.
        The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial.
        Lancet. 2006; 368: 476-482
      2. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48 week results from AI424-089 (abstract 107LB). Presented at the 13th Conference on Retrovirus and Opportunistic Infections, February 5–8, 2006, Denver, CO.

        • Robbins GK
        • De Gruttola V
        • Shafer RW
        • et al.
        Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
        N Engl J Med. 2003; 349: 1850-1861
        • DeJesus E
        • Herrera G
        • Teofilo E
        • et al.
        Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
        Clin Infect Dis. 2004; 39: 1038-1046
        • Kottilil S
        • Polis MA
        • Kovacs JA
        HIV infection, hepatitis C infection, and HAART: hard clinical choices.
        JAMA. 2004; 292: 243-250
        • Fundaro C
        • Genovese O
        • Rendeli C
        • et al.
        Myelomeningocele in a child with intrauterine exposure to efavirenz.
        AIDS. 2002; 16: 299-300
        • Food and Drug Administration
        FDA/Bristol Myers Squibb Issues Caution for HIV Combination Therapy with Zerit and Videx in Pregnant Women. US Department of Health and Human Services, Rockville, MDJanuary 5, 2001 (Talk Paper T01-02.)
        • Miller KD
        • Cameron M
        • Wood LV
        • Dalakas MC
        • Kovacs JA
        Lactic acidosis and hepatic steatosis associated with the use of stavudine: a report of four cases.
        Ann Intern Med. 2000; 133: 192-196
        • Hitti J
        • Frenkel LM
        • Stek AM
        • et al.
        For the PACTG 1022 Study team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
        J Acquir Immune Defic Syndr. 2004; 36: 726-772
        • Sterne JA
        • Hernan MA
        • Ledergerber B
        • et al.
        Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.
        Lancet. 2005; 366: 378-384
        • Mellors J
        • Munoz A
        • Giorgi JV
        • et al.
        Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
        Ann Intern Med. 1997; 126: 946-954

      Uncited references

        • Reisler RB
        • Murphy RL
        • Redfield RR
        • Parker RA
        Incidence of pancreatitis in HIV-1 infected individuals enrolled in 20 AIDs clinical trials group studies: lessons learned.
        J Acquir Immune Defic Syndr. 2005; 35: 159-166
        • Fernandez Guerrero ML
        • Rivas P
        • Molina M
        • Garcia R
        • De Gorgolas M
        Long-term follow up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
        Clin Infect Dis. 2005; 41: 390-394

      Linked Article

      • Erratum
        The Journal for Nurse PractitionersVol. 3Issue 10
        • Preview
          An error appears in Table 3 of the article “Treatment for Adult HIV Infection: Antiretroviral Update and Overview” in the October 2007 issue (page 620). The DHHS Panel Recommendations for patients with asymptomatic CD4 + T cell count/mm3 < 350 should read: “Most clinicians defer treatment, but some will provide treatment for plasma viral loads ≤ 100,000 copies/mL.”
        • Full-Text
        • PDF